Scalable microfluidics that can address the challenge of delivery of large transgenes to therapeutic cells

To accelerate the manufacturing innovation, the goal of this project is to validate a cell engineering technology that uses a microfluidic transfection for delivery of therapeutic transgenes to four cell types of importance to the pharma industry.
Categories
Cell and Gene therapies
Equipment and Supplies
Project status
100% Completed

Industry Need

Cost of manufacturing genetically engineered cells for therapies is significant, with high process complexity, and variable cell product quality. 

Solution

Validate a cell engineering technology that uses microfluidic transfection for delivery of therapeutic transgenes.

Outputs/Deliverables

  • Developed consumable transfection chip for T cells and iPSCs that was delivered to partners
  • Demonstrated first mechanoporation transfection of iPSCs with large CRISPR-correction plasmids
  • Demonstrated high efficiency T cell knockout editing using mechanoporation
  • Demonstrated clinical scale processing (>1B cells) of T cells

Additional Project Information (Members Only)

Login to the NIIMBL member portal to access more, including: 

  • Updates
  • Value Proposition
  • Related Publications
  • Deliverables

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

Georgia Tech Research Corporation

Georgia Tech Research Corporation

Participating Organizations

Bristol-Myers Squibb

Bristol-Myers Squibb

CellFE, Inc.

CellFE, Inc.

Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC

National Institute for Pharmaceutical Technology and Education, Inc (NIPTE)

National Institute for Pharmaceutical Technology and Education, Inc (NIPTE)